Joakim Nyberg, Ph.D.

Principal Consultant, Enabler Leader & Board Member


  • Co-founded Pharmetheus in 2012, actively working in client projects, with continuous improvements, and managing the Enabler Team, including the subteams IT, Data Programming, and Technical Solutions.
  • Expertise includes pharmacometrics, trial design, and systems development in therapeutic areas such as diabetes, oncology, and rare diseases.
  • Experience as Researcher at Uppsala University, Sweden, where he has a part-time position to perform pharmacometric research, primarily by supervision of Ph.D. students. Previously, he worked as System Developer at B&M Systemutveckling AB, Sweden.
  • M.Sc. in Engineering Physics (2006) and Ph.D. in Pharmaceutical Biosciences (2011) from Uppsala University, Sweden.
LinkedInGoogle Scholar

Pharmetheus affiliated publications

A framework for prediction of progression free survival based on modelling of sub-endpointsChecklists and best practices to support the informed use of Forest plots to illustrate the impact of covariates in pharmacometric modelsExposure–Response Analyses for the MET Inhibitor Tepotinib Including Patients in the Pivotal VISION Trial: Support for Dosage RecommendationsAn Introduction to the Full Random Effects ModelGeneralized FOCE with PumasA Quantitative Approach to the Choice of Number of Samples for Percentile Estimation in Bootstrap and Visual Predictive Check AnalysesSensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity StudiesModel Based Support to Biosimilarity Assessment Planning – A Case Study of PegfilgrastimImplicit and Efficient Handling of Missing Covariate Information Using Full Random Effects ModellingProperties of the Full Random Effect Modelling Approach With Missing CovariatesPharmacokinetic and Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients with Prior Myocardial Infarction (PEGASUS-TIMI 54)